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Open access under CC BRisk assessment of cosmetic ingredients represents a regulatory standard requirement in Europe and
other regions. An integrated approach was designed to assess the safety of HPC, a particulate composite
of hydroxyapatite and protein (gelatin) for use in oral care products, employing a weight-of-evidence
assessment and considering speciﬁc physico-chemical properties and exposure conditions. An initial
evaluation of the constituents suggested that their chemical nature does not represent a particular health
hazard per se. Hydroxyapatite is the main component of teeth and bones in mammals; gelatin is used in
food and assumed to be safe once a BSE/TSE risk has been excluded. In vitro screening tests were chosen
to further evaluate the biocompatibility: Hen’s egg test-chorioallantoic membrane (HET-CAM) to assess
irritating effects towards mucous membranes; MTT cytotoxicity test with 3T3 ﬁbroblasts; human corneal
epithelial models to investigate inﬂammatory mediators and cytotoxicity; macrophage assays to measure
cytotoxicity, inﬂammatory mediators and oxidative stress. Together with results from clinical studies,
exposure estimates and analyses of kinetic properties, the presented information provides sound evi-
dence to support the safe use of HPC. This is an example of a risk assessment for cosmetic use of small
particles without the need for additional animal studies.
 2010 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Sensitive teeth still present an unsolved problem in practical
dentistry. It is commonly accepted that exposure of dentine to
the conditions in the oral cavity is the main reason for this phe-
nomenon. It has been reported that approximately 36% of adults
in the United States and Western Europe may suffer from sensitive
teeth (Addy, 2002) and it is likely that the incidence will increase
because of the demographic development. The hydroxyapatite–
protein-composite HPC represents an active ingredient inETOC, European Centre for
, European Center on the
ramagnetic resonance; GCP,
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CP, Scientiﬁc Committee on
S, Scientiﬁc Committee on
ransmission electron micros-
ble tetrazolium salt 1; XTT,
trazolium]-bis(4-methoxy-6-
).
Y-NC-ND license.toothpaste especially suited to protect sensitive teeth. HPC has
been demonstrated to adsorb to the surface of exposed dentine,
inducing the crystallization of calcium and phosphate from the sal-
iva to grow a thin protective layer which covers the dentin tubuli
that conduct unpleasant stimuli to the nerve, thereby preventing
pain induction caused by external stimuli like hot/cold or sweet/
sour food and drinks (Henkel, 2005).
The natural mineralization repair mechanism of the saliva thus
is used in a self-organizing process which can be referred to as neo-
mineralization. In general, engineered hydroxyapatite materials
and their composites are intended for a variety of biomedical appli-
cations, often serving as bone substitute in intraosseous implanta-
tion or as implant coating materials, including small particle sizes
down to the nano range (Arts et al., 2006; Huber et al., 2007,
2006c; Palmer et al., 2008; Webster and Ahn, 2007).
According to European Cosmetics legislation (EC, 1976), a cos-
metic product is only allowed to be marketed if it has been proven
to be safe for the consumer. Toothpaste, like any other cosmetic
product, therefore requires a thorough risk assessment which is
essentially based on the safety of its ingredients. Information on
the properties of the formulation (e.g. clinical data) can be included
in the assessment. Legal restrictions to testing of ingredients and
formulations are provided in Directive 2003/15/EC (EC, 2003),
where a phasing out of animal testing is laid down (animal testing
ban).
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ticles is ongoing for many decades and is to a large extent related
to potential risks following inhalative exposure, e.g. (Schmid et al.,
2009). Especially ultraﬁne or nanoparticles are in the focus of the
debate, e.g. (ECETOC, 2005; Holsapple et al., 2005), usually meant
to have one or more size dimensions between 0.1 and 100 nm.
Due to the diversity of particulate materials and their applica-
tions, no ﬁxed scheme is applicable to assess the potential risk of
small particles. Consequently, a speciﬁc, taylor-made risk
assessment and testing strategy needed to be designed for HPC,
consisting of several building blocks. This strategy comprises a
weight-of-evidence (WoE) analysis which is often used to assess
the potential hazard, including multiple elements like physico-
chemical characterization, available information on constituents,
in vitro screening tests and clinical studies.
The assessment of biocompatibility is a key request in this re-
gard. When selecting suitable test systems for tooth paste ingredi-
ents, speciﬁc attention needs to be paid to the local compatibility
towards mucous membranes as the primary site of contact.
Beyond that, it needs to be investigated whether a particulate
material can penetrate into the body leading to systemic exposure.
In case part of the material should become systemically available,
the investigation of potential interactions with cells is of particular
interest, mainly the responses of macrophages as the ﬁrst line of
defense of the body. Cytotoxicity, inﬂammation and oxidative
stress through reactive oxygen species (ROS) formation are consid-
ered to be relevant to the potential development of several chronic
diseases (Borm et al., 2006; Brown et al., 2001; Donaldson et al.,
2005; Hirvonen et al., 1996; Lewinski et al., 2008; Unfried et al.,
2007) and consequently need to be included in the analysis. To ﬁ-
nally assess the relevance of effects, information on the biodegrad-
ability of the material under consideration is also of importance.
This study aims at describing the whole process of the risk
assessment of HPC, comprising the initial description of scientiﬁc
objectives, the identiﬁcation of information requirements and data
gaps, the selection of suitable non-animal methods to generate
missing data and the subsequent integration of all relevant infor-
mation into a comprehensive assessment.2. Materials and methods
2.1. Integrated risk assessment and weight-of-evidence (WoE) analysis
‘‘Integrated risk assessment’’ is not a standardized term and is
used in a number of different contexts (Bridges and Bridges,
2004). In our study it describes a qualitative, expert judgment-
based integration of data from different sources to assess the safety
of consumers for the intended and foreseeable use of a cosmetic
ingredient.
In particular for the hazard assessment part, the risk assessment
is making use of a WoE analysis, a term which has also been used
in many different ways in the public literature (Weed, 2005). We
refer to WoE as a systematic, expert-judgment based approach to
assess available information relevant for human safety and to iden-
tify potential data gaps, triggering a tiered testing approach. Test-
ing results in turn were included in the overall WoE analysis, and
exposure estimates were performed. The process was continued
until a responsible safety decision could be made based on the cur-
rent knowledge (with the general option for re-evaluation as soon
as new relevant knowledge becomes available).2.2. Strategy of literature search and review
In addition to retrieval of supplier information on the constitu-
ents, a literature search on the biocompatibility and toxicologicalproﬁle of gelatin and hydroxyapatite or composites thereof was
performed in PubMed and other databases or networks (TOXNET
(US National Library of Medicine), Ariel™/ChemEXPERT, other
internet sources, in-house databases). Hits were ﬁrst screened for
relevance to the issue by reading the abstracts. Additional refer-
ences were identiﬁed through cross-references and additional
searches on speciﬁc topics. About 80 references were selected in
summary for detailed review with a particular focus on papers
with well-documented materials and procedures which are appli-
cable to this assessment.
2.3. Test samples
Synthesis and characterization of HPC was described previously
(Albrecht et al., 2009). In brief, HPC is synthesized by a co-precip-
itation of calcium chloride dihydrate, collagen (gelatin with an
average molecular weight of 140,000 Da with a molecular weight
distribution between approx. 6000 and >400,000 Da) and ammo-
nium phosphate. The calcium/phosphorus ratio was analyzed with
inductively coupled plasma (ICP) spectroscopy and equals to
1.95 ± 0.28. The protein content is 36.2%. Particle morphology
and size were analyzed by transmission electron microscopy
(TEM), showing irregular shaped particles in the micrometer range
with average sizes of 1200  2100 nm; pictures shown in (Albrecht
et al., 2009). The speciﬁc surface is 67 m2/g as analyzed by the
Brunauer–Emmet–Teller (BET) method. For formulation into cos-
metic products, HPC (9.5%) is provided in a preserved dispersion
of glycerol (15%) and water (73%). In order to speciﬁcally investi-
gate the properties of HPC, the material was used in cellular test
systems without preservative (due to the known cytotoxic effects
of preservatives) and also was isolated from the sediment. The ﬁnal
concentration of HPC in a marketed toothpaste is approx. 0.1%.
Trade names for HPC are Nanit or Nanitactive (glycerol
dispersion).
Depending on the speciﬁc test system, a number of controls and
reference substances were applied along with HPC. An overview of
test samples is provided in Table 1. Pure hydroxyapatite without
gelatin was produced in an analogous precipitation process as
HPC but without the presence of gelatin (HA-NP). This material
was used either as sediment (macrophage tests) or as 5.3% glycerol
dispersion (HCE and 3T3 experiments). Two other HA materials,
HA-NR (hydroxyapatite – nano, rods) and HA-FN (hydroxyapatite
– ﬁne/dull needles), were prepared with different sizes and mor-
phologies as previously described (Albrecht et al., 2009) and in-
cluded in macrophage experiments. Ostim (Heraeus Kulzer,
Hanau, Germany; abbreviated as HA-NN (hydroxyapatite-nano/
needle-shaped) in the following), a bone grafting material ap-
proved for clinical use, was used as a benchmark control in most
in vitro tests. The calcium/phosphate ratio of this material is 1.67,
the surface area/mass is 106 m2 g1 (Huber et al., 2007).
2.4. HET-CAM (Hen’s egg test-chorioallantoic membrane) to assess
mucosal membrane irritation
The HET-CAM was carried out as previously described (Steiling
et al., 1999) using the reaction time method for transparent and
the endpoint assessment for non-transparent test items. In brief,
fertilized eggs were incubated for 9 days prior to use. Six eggs were
used for each test item: HPC (gd) and two dilutions thereof with 1%
and 5% HPC, tooth gel with 1% HPC, standard reference toothpaste
(Sensodyne Fresh Mint). Of the dispersions 300 ll were applied to
the CAM. The irritation potential is evaluated by occurrence of spe-
ciﬁc effects to the membranes and/or vessels (hemorrhage (H), ly-
sis (L), coagulation (C)) which are interpreted in comparison to 5%
sodium magnesium lauryl-myristyl-6-ethoxysulphate (Texapon
ASV, Cognis, Germany). This internal reference compound is
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compound to the rabbit eye in vivo. In the reaction time method
any reactions occurring within 5 min are observed and an irritation
quotient (Q) is calculated; in the endpoint assessment, the sub-
stance is rinsed after 30 s before observations are made and the
sum of scores (S) for the six eggs is determined. The most pro-
nounced effects (highest S-value) are then used to translate results
into four categories which are deﬁned as follows: Q 6 0.8 or S 0–5:
slightly irritating, Q > 0.8 to >1.2 or S 6–12: moderately irritating,
QP 1.2 to <2.0 or S 13–15: irritating, QP 2 or S 16–18: severely
irritating (R41).
2.5. Cytotoxicity and inﬂammation
2.5.1. Viability of 3T3 ﬁbroblasts (MTT test)
Balb/3T3 A31 mouse ﬁbroblasts were cultured in 75 cm2 culture
ﬂasks (Sarstedt, Nümbrecht, Germany) in Dulbecco’s Modiﬁed
Eagle Medium (DMEM, Gibco, Eggenstein, Germany) with 10% fetal
calf serum (FCS; Gibco, Eggenstein, Germany) and 2% penicillin/
streptavidin (Gibco, Eggenstein, Germany) at 37 C and 5.0% CO2.
Log phase cultures were harvested and pipetted in 96-well
plates at a concentration of 3000 cells per well in 100 ll culture
medium. The cell culture plates were incubated for 48 h at 37 C,
5.0% CO2/95% air. After incubation subconﬂuency of cells and nor-
mal morphology was veriﬁed. The culture medium was removed
and replaced with test sample dilutions of three HA samples
(HA-NN, HA-NP (gd), HPC (gd)): 5%, 2.5%, 1.0%, 0.5%, 0.1% for 24 h.
Following twofold washing with phosphate-buffered saline (PBS;
2  0.2 ml) viability was determined by a modiﬁed MTT (3-(4,5-di-
methyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) assay
(Mosmann, 1983) which has been widely used as a colorimetric
approach based on the activity of mitochondrial dehydrogenase
enzymes in cells (Sigma–Aldrich, Taufkirchen, Germany). After
incubation with test samples, cell cultures were incubated with
MTT solution at 37 C for 3 h and extracted with isopropanol for
1 h. The OD was analyzed at 540 nm with a spectral photometer
(SpectraMax, MDS Analytical Technologies, Ismaning, Germany).
Cell culture medium was used as negative control and the deter-
gent sodium dodecylsulphate (SDS; 0.01%) as positive control. For
all test samples and controls 6 replicas were used.
Statistical analysis was performed with MicrosoftOfﬁce Excel
2003 (1985–2003, Microsoft Corporation) software for basic evalu-
ation and graphical editing; Friedmans ANOVA, a non-parametrical
test suited to detect differences in treatments across multiple test
attempts, and the sign test, a non-parametric test to compare inde-
pendent pairs of sample data, were performed with STATISTICA 8.0
software (StatSoft, Inc. 1984–2008, Tulsa, USA).
2.5.2. Mucosa-like human corneal epithelial (HCE) tissue models (LDH
release; IL-1a release)
The SkinEthic HCE model represents a three-dimensional hu-
man corneal mucosa model. When cultivated on a polycarbonate
ﬁlter, the immortalized human corneal epithelial cells from the cell
line HCE reconstruct a corneal epithelial tissue (mucosa), devoid of
stratum corneum, ultra-structurally (tissue morphology and thick-
ness) similar to the corneal mucosa of the human eye. (SkinEthic
Laboratories, Nice, France, www.skinethic.com.)
Following pre-incubation of HCE tissues models in SkinEthic
HCE culture medium overnight, models were treated with 50 ll
of test samples (0.5% and 1% of each HPC, HA-NP and HA-NN) for
3 min by simulating slight mechanic stress (tooth brushing) by
placing the cultures on a shaker and rinsed afterwards two times
with 0.5 ml PBS (phosphate-buffered saline). Potential delayed ef-
fects were addressed by adding an 18 h incubation period. Samples
of culture medium were analyzed for membrane integrity (LDH re-
lease) and the presence of irritation/inﬂammation markers (IL-1
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HCE models as a negative control.
The LDH assay was performed with a commercially available
LDH-Cytotoxicity Detection Kit (Roche, Mannheim, Germany)
according to the instructions of the manufacturer. IL-1a release
was detected by using the Human IL-1a/IL-1F1 Quantikine ELISA
Kit (R&D Systems, Minneapolis, USA) according to the instructions
of the manufacturer. For all test samples and controls P5 replicas
were used (for details see Section 3).
Histological analysis was performed for HPC, HA-NP and SDS
treated models. Models were ﬁxed in 10% formalin and embedded
in parafﬁn according to standard procedures. Parafﬁn slices were
stained with hematoxylin/eosin.
Statistical analysis of experiments described in Sections 2.5.1
and 2.5.2 was performed with MicrosoftOfﬁce Excel 2003
(1985–2003, Microsoft Corporation) software for basic evaluation
and graphical editing; Kruskal–Wallis-ANOVA, a non-parametric
method for testing equality of population medians among groups,
and the Mann–Whitney U test, a non-parametric signiﬁcance test,
were performed with STATISTICA 8.0 software (StatSoft, Inc. 1984–
2008, Tulsa, USA).
2.5.3. Macrophage assays
Assays with murine RAW264.7 macrophages, rat NR8383 and
primary macrophages were performed as described previously
(Albrecht et al., 2009; Scheel et al., 2009). In brief, RAW264.7 cells
were treated with different concentrations of HPC, HA-NP, HA-NR,
HA-NN and DQ12 quartz and LPS as positive controls to determine
cell viability (XTT-test), TNF-a and NO release with commercially
available test kits. For details see (Scheel et al., 2009).
NR8383 macrophages were treated with different concentra-
tions of HPC, HA-NP, HA-NR, HA-NN, HA-NF and DQ12 quartz and
LPS as positive controls to determine cell viability (WST-1 assay)
and TNF-a release with commercially available test kits; oxidative
stress was determined by EPR. The WST-1 test and EPR were addi-
tionally performed with primary macrophages. For details see
(Albrecht et al., 2009).
2.5.4. Clinical studies
Two randomized, double blind, parallel-group, positive-stan-
dard controlled studies have been commissioned and performed
according to Good Clinical Practice (GCP).
In Study 1, two toothpaste formulations with 0.1% net content of
HPC were compared against a toothpaste for sensitive teeth as a
benchmark. Besides the assessment of sensitivity as major efﬁcacy
parameter, the criteria relevant for the evaluation of safety and tol-
erability were as follows: adverse events collection, bucco-dental
examination, gingival index, change of the teeth color and the
amount of plaque, cosmetic acceptance questionnaire. The analysis
of the included 90 subject’s characteristics and safety data was per-
formed using individual data listings and descriptive statistics
(planned: 90, screened/enrolled: 121, in safety analysis: 90; groups
of 30 subjects tested 1 toothpaste each, completed trial: 89 (1
withdrawal in one of the test toothpaste groups)).
In Study 2 planned with 90 subjects (enrolled: 111, completed
trial: 105) the combination of a standard toothpaste with a HPC
tooth-gel formulation (1.5% HPC; treatment group size 38 persons
in the beginning/37 in the end of the study) and a HPC gel-strip (4%
HPC; treatment group size 37/37) were tested against a toothpaste
for sensitive teeth as a benchmark (treatment group size 36/31). In
analogy to Study 1, safety and tolerability were assessed in addition
to the sensitivity assessment using results of bucco-dental exami-
nation and overall cosmetic questionnaire, and by incidence and
severity of adverse events. Safety (oral and dental examination)
and tolerability evaluations (adverse events) were listed by
treatment group and subject number and described by treatmentgroup using frequency tables on the ‘‘Intent to Treat’’ (ITT)
population.
2.6. Exposure and kinetics
2.6.1. General exposure estimate and overview
A general analysis of consumer exposure was calculated accord-
ing to average values proposed by the EU Commission’s scientiﬁc
advisory panel for issues concerning safety of consumer products
SCCS (formerly termed SCCP) (SCCP, 2006). Further ADME consid-
erations were based on practical (Section 2.6.2) and theoretical
toxicokinetic considerations, literature data and expert consulta-
tion, as well as penetration behavior of HPC in mucosa-like tissue
models as analyzed by Cryo-TEM (Section 2.6.3).
2.6.2. Dissolution behavior of HPC in simulated gastric ﬂuid
General information on the stability/solubility of HA and gelatin
was initially obtained from general knowledge and literature. The
dissolution of HPC was further investigated in simulated gastric
ﬂuid (SGF), an aqueous dilution of HCl. For preparation of SGF,
1.5 ml HCl (Roth, Rotipuran, p.a., >32%) were added to 1.5 l H2O
(demineralized) to result in a pH value of approx. two.
The calcium content of HPC was analyzed by ICP (inductively
coupled plasma) spectrometry. 1.5 g HPC (sediment) was pre-
incubated with 100 ml H2O (demineralized) and stirred for
25 min at 400 rpm at room temperature, then transferred to centri-
fuge tubes and centrifuged for 15 min at 1000g. The supernatant
was removed and analyzed for its calcium content by IPC. The sed-
iment was added to 500 ml SGF and stirred for 2 h. The calcium
content of the solution was again analyzed by ICP. The total
amount of dissolved HPC was calculated based on the calcium con-
tent in HPC as determined by IPC and by referencing the stoichiom-
etry of HA. Measurements were carried out in duplicate.
2.6.3. HCE penetration screening (Cryo-TEM)
HCE models (treated with HPC, HA-NP and HA-NN as described
in Section 2.5.2) were investigated in Cryo-TEM analysis. The water
contained in the HCE models was exchanged stepwise against eth-
anol (Merck, Darmstadt, Germany) by incubating the tissue models
for 30 min each with an aqueous dilution of 30% ethanol v/v, 50%
ethanol, 70% ethanol, 90% ethanol and 100% ethanol (3  30 min).
Then ethanol is exchanged against propylene oxide (Merck,
Darmstadt, Germany) by incubating with 100% propylene oxide
2 for 15 min, then propylene oxide against Epon 812 (Serva, Hei-
delberg, Germany) for ﬁnal embedding of the tissue. Ultraﬁne
slices were prepared from the samples, contrasted with uranyl ace-
tate (Serva, Heidelberg, Germany) and subjected to TEM analysis
(Philips CM12). Samples were prepared and analyzed in triplicate
by inspecting particles in the different compartments of the tissue
models without statistical evaluation.3. Results
3.1. Assessment and testing strategy for hazard
The design of the assessment and testing strategy took the fol-
lowing elements into account:
– What is the available hazard information for HPC including data
on starting materials; do these hazard characteristics suggest a
safety concern?
– Is there need to further evaluate the potential hazard of HPC?
Which additional tests are suitable to address the relevant
questions? Which are appropriate benchmark and control
samples?
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(including nanoscale material)?
– Which overall conclusion can be drawn regarding the safety of
HPC under normal conditions of use?
The main building blocks of the risk assessment are displayed in
Fig. 1. Following initial assessment of available data, in vitro studies
were chosen to further assess the biocompatibility of HPC. WoE ex-
pert judgment was used in each step to take a decision if available
information is sufﬁcient or not and to choose suitable further tests
where necessary. In the test design, exposure considerations were
included to target typical concentrations of HPC in oral care prod-
ucts (e.g. approx. 1% HPC (gd) or 0.1% HPC in toothpaste). Results of
these tests were compared to observations from clinical studies.
The speciﬁc rationale for each element of the assessment is de-
scribed in more detail in the section below.
3.1.1. Basic toxicological proﬁle of the constituents. Review of supplier
information and publicly available data
Rationale: The logical ﬁrst step in any assessment of hazard or
risk is to review available information. The outcome of the expert
evaluation will be an initial assessment and a judgment whether
information is still missing or not.
3.1.1.1. Hydroxyapatite (HA) and composites thereof. Hydroxyapatite
is a naturally occurring phosphate mineral, which is the main com-
ponent of teeth and bones in mammals. It is a well-established
medicinal product which is considered suitable and safe material
intended for intraosseous implantation and which is widely used
in practical dentistry (Heraeus Kulzer GmbH, 2005; Huber et al.,
2006a,b,c,d; Kumta et al., 2005; Thorwarth et al., 2004).
A large number of studies on hydroxyapatite in biomedical
applications report good biocompatibility and biodegradability of
the material, which is used in various speciﬁcations (e.g. dense,
coating, granules, powders/dispersions, various sizes and shapes)
and under different conditions, e.g. implants, bone ﬁlling (for pri-
mary hits in a recent PubMed search see Fig. 2). In general, the
material causes no inﬂammatory reaction at the site of administra-
tion and does neither induce acute nor chronic toxic effects.
(Bloebaum et al., 1998; Cui et al., 1996; Guo et al., 1999; Huang
et al., 2004; Liu et al., 1997; Rumpel et al., 2006; Troﬁmov et al.,
1996; Wenisch et al., 2003). Speciﬁcally, data on HA-collagen com-
posites has been reviewed and supports the biocompatibility both
in humans and animals (Wahl and Czernuszka, 2006).
Commercially available hydroxyapatite is not classiﬁed as haz-
ardous; the acute toxicity is extremely low: LD50oral,rat >25,350 mg/
kg (Merck, 2000). A nano-sized HA dispersion, Ostim, has under-
gone comprehensive preclinical evaluation including biocompati-
bility and genotoxicity testing (Rudin et al., 1994) and received
regulatory approval for biomedical applications in Europe (CE cer-
tiﬁcate) and the US (FDA approval). Several studies for clinical
applications have been published (Arts et al., 2006; Heraeus Kulzer
GmbH, 2005; Huber et al., 2006a,b,c,d, 2007; Kilian et al., 2002;
Kumta et al., 2005; Laschke et al., 2007; Rauschmann et al.,
2005; Thorwarth et al., 2004). Several nanoscalar HA materials
were investigated and used for dentistry/implantation, local drug
delivery and cosmetics, e.g. as root ﬁlling material (Busso, 2009).
Besides Ostim, a number of other HA materials have been
tested for mutagenicity in various in vitro and in vivo assays while
part of the assays were performed directly with the HA or HA com-
posite materials, others with eluates thereof. Reports include the
protocol of Ames (Guo et al., 1999; Jantova et al., 2008; Liu et al.,
1997; Suzina et al., 2004), micronucleus test (MNT) (Guo et al.,
1999; Liu et al., 1997; Ye et al., 2004), Comet assay (Jantova
et al., 2008), HPRT (Jantova et al., 2008) and chromosome aberra-
tion (Kannan et al., 2004a,b). Though studies were usually notperformed according to internationally approved protocols (like
OECD technical guidelines), there is strong evidence that genotoxic
and mutagenic effects of HA can be considered unlikely. Some
in vivo studies explicitly investigated possible carcinogenicity with
no positive ﬁndings (Landi et al., 2008; Takamura et al., 1994). No
reports on tumor formation due to HA exposure could be found in
the literature which is also true for other adverse subchronic or
chronic effects.
Another observation is that HA has a well-known binding
capacity for DNA and proteins, a fact that is used extensively in
DNA and protein chromatography as well as in pharmaceutical re-
search for delivery agents of proteins and DNA (Kumta et al., 2005).
Regarding the relevance for the assessment of genotoxic effects,
however, there is no evidence that adverse reactions occur upon
contact with cells through direct interaction with nuclear DNA.
Also, in contrast to intercalating agents like ethidium bromide,
DNA binding to HA is non-covalent, pH-dependent and allows re-
elution (e.g. with increased concentrations of phosphate buffer).
Upon uptake in macrophage cells, it has been demonstrated
that nano HA particles were dissolved progressively in lysosomes.
Enhanced cytotoxicity towards macrophages was observed with
extremely small particles (approx. 50  20 nm) compared to larger
particles on the basis of mass/volume. It was speculated that
increasing intracellular calcium level following HA dissolution
could be the main reason for cytotoxicity and apoptosis observed
in such studies (Motskin et al., 2009).
No allergic skin reactions have been reported in clinical studies
including those with speciﬁc investigation of potential allergenic
effects (Kannan et al., 2004a,b; Li et al., 2008; Pankratov et al.,
1994; Rajab et al., 2004; Suzina et al., 2004).
Physical particle properties like surface area, size and morphol-
ogy were reported to potentially inﬂuence the biocompatibility of
different hydroxyapatite materials on speciﬁc cellular systems
(Evans, 1991; Grandjean-Laquerriere et al., 2005; Laquerriere
et al., 2003). Needle-shaped particles, for instance, were reported
to induce larger production of cytokine IL-18 compared to other
morphologies (Grandjean-Laquerriere et al., 2004).
Summary of literature review and implications for testing needs:
HA is a naturally occurring phosphate mineral, which is the main
component of teeth and bones in mammals and is used in a variety
of biomedical applications. Literature shows that also small dimen-
sions do not necessarily produce a risk to human health. However,
some studies have associated cytotoxic effects, enhanced inﬂam-
matory mediators and other variations of biomarkers with HA
particle size in speciﬁc cell cultures. There is not yet enough infor-
mation available to deduce robust rules from hydroxyapatite spec-
iﬁcations to its toxicologically relevant properties. Since there is no
standard, ofﬁcially accepted method or approach to assess the haz-
ard of small particles, including the choice of the cell or tissue sys-
tem and application of the test samples, the relevance of the test
conditions to the physiological situation needs to be critically as-
sessed. An individual assessment of each material is needed which
might comprise at least some in vitro testing, in particular to assess
inﬂammatory effects and cytotoxicity towards cells. Ostim as an
ofﬁcially approved medical product seems to be a valuable
benchmark to be included in the testing of particulate HA
materials.3.1.1.2. Gelatin. Gelatin is a naturally occurring polymer/protein.
The used gelatin is of no BSE (Bovine Spongiform Encephalopathy)
source as ensured by a BSE-Certiﬁcate from the manufacturer. Also,
being produced from animal sources, it was assured that the mate-
rial does not present a TSE (Transmissible Spongiform Encephalop-
athy)/BSE risk applying state-of-the-art criteria. No hazards are
expected based on the nature of gelatin and its long-standing use
RISK ASSESSMENT 
Toxicological information on the constituents (gelatin and hydroxyapatite): 
Literature data and supplier’s information for the bulk material (basic 
assessment); data search to also include information on nanoscalar 
hydroxyapatite to complement the assessment
In vitro Screening Tests  to further assess/support the assumptions derived 
from the initial evaluation: test for irritation, inflammation, cytotoxicity, oxidative stress 
Clinical studies to approve biocompatibility in humans 
Weigth-of-evidence HAZARD ASSESSMENT of HPC
EXPOSURE ASSESSMENT of HPC 
Generic exposure estimate according to SCCS guidance 
Consideration of physico-chemical properties (e.g. solubility in acid 
medium) 
Consideration of potential mucosal penetration 
Literature/theoretical considerations + in vitro screening experiment  
Physicochemical Characterization
Fig. 1. Building blocks of the integrated safety assessment strategy for HPC.
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verse effects of gelatin therefore was not considered necessary.3.1.2. In vitro screening tests
As a result of the initial assessment, it was concluded that the
biocompatibility of a new HA material should be speciﬁcally tested
with a focus on potential inﬂammation, oxidative stress and cyto-
toxic effects since these effects are of major concern in relation to
small particle sizes. The interpretation of effects should be done in
comparison with appropriate benchmark controls and might in-
clude a comparison with HA in other physical forms.
When selecting the in vitro test battery for HPC and deﬁning the
individual test designs, the foreseeable conditions of use were ta-
ken into account. Test concentrations were chosen to cover the
typical concentration in products. In addition, technical limitations
were considered, like in the case of cell culture experiments, the
applied concentrations should not produce overload effects in or-
der not to create misleading results and artifacts. The following
test systems were selected which represent valuable routineprotocols to provide relative estimates of the properties of test
samples: Section 3.1.2.1 estimation of the irritating potential to-
wards mucous membranes in the HET-CAM, Section 3.1.2.2 cell
viability (MTT) assay in 3T3 ﬁbroblasts, Section 3.1.2.3 LDH and
IL-1a measurement in HCE models, Section 3.1.2.4 investigation
of inﬂammatory and cytotoxic effects as well as induction of oxida-
tive stress in three different macrophage test systems. The ratio-
nale for the choice of each test system is described below in
more detail.3.1.2.1. HET-CAM. Rationale: Assessment of potential irritating
effects towards mucous membranes as an important aspect of bio-
compatibility. The CAM represents a sensitive, highly vascularized
membrane suitable to detect potential irritating effects towards
eyes and mucous membranes. A good concordance of HET-CAM re-
sults with in vivo data of the Draize test could be found (Steiling
et al., 1999). Henkel has a 20 years in-house experience with this
test for the assessment of a variety of raw materials and
formulations.
(“hydroxyapatite” OR “hydroxylapatite”
OR “hydroxy apatite” OR “hydroxyl apatite”) 
16000 hits
AND
AND
3174189"biodegradation"
1101517256("biodegradability" OR "biodegradable")
00002"free" AND "radical" AND "formation"
1062271"inflammation"
011137("reactive" AND "oxygen" AND "species" OR ROS)
022016"oxidative" AND "stress"
000030("carcinogenicity" OR "carcinogenic")
000024("mutagenicity" OR "mutagenic") 
000019("genotoxicity" OR "genotoxic")
7610114693823("biocompatibility" OR "biocompatible")
12194199("cytotoxicity" OR "cytotoxic") 
52164341("toxicity" OR "toxic")
NTNMNPNC
AND
140NT = “nanotechnology”
23NM = ("nanomaterial" OR "nanomaterials")
275NP = ("nanoparticle" OR "nanoparticles")
130NC = ("nanocomposite" OR "nanocomposites")
Fig. 2. PubMed search for toxicological information on hydroxyapatite. Example of a PubMed search in December 2009 for toxicologically relevant information on
hydroxyapatite, displaying the initial search terms and hits.
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HPC (gd) are displayed in Table 2. None of the formulations is clas-
siﬁed as irritating or severely irritating in this test system. HPC (gd)
was found to be ‘‘slightly irritating’’ (lowest category) up to the
highest concentration and less irritating than a tooth gel formula-
tion and a standard toothpaste formulation.3.1.2.2. Viability of 3T3 ﬁbroblasts (MTT test). Rationale: Assessment
of biocompatibility, particularly cell viability. 3T3 cells represent a
sensitive test system in combination with the MTT assay. Even be-
fore fatal destruction of cells, this assay is able to detect adverse
cellular events, namely metabolic dysfunction of enzymes leading
to decreased performance as detected by a colorimetric readout.
This test might be complemented by another assay as many differ-
ent conditions can increase or decrease metabolic activity. The
MTT assay have been frequently used for the assessment of thebiocompatibility of dental materials, e.g. (Schweikl and Schmalz,
1996; Torrado et al., 2005).
Cell vitality was measured following treatment of 3T3 cells with
different concentrations of test samples. The application of HPC
(gd) and the other test samples tested up to a concentration of
5% did not markedly affect cell viability. Results are displayed in
Fig. 3.
3.1.2.3. Mucosa-like tissue models (LDH and IL-1a release). Rationale:
Assessment of biocompatibility towards mucous membranes, par-
ticularly cell viability and inﬂammation. LDH release indicates
severe and fatal cell damage (disruption of outer cell membranes).
IL-1a is a common marker for inﬂammation and considered to be a
signiﬁcant factor for the development of a number of chronic ef-
fects. The three-dimensional HCE models are suited to investigate
mucous membrane irritations and resemble more closely the phys-
iological conditions than 3T3 cell culture. Amongst a number of
Table 2
Results of the HET-CAM.
Test samples Reaction time method (Q) End point assessment (S) Evaluation
H L C
HPC (gd)a, dilution 1 (1% HPC) 0.02 (±0) – – – slightly irritating
HPC (gd)a, dilution 2 (5% HPC) – 0 0 0 slightly irritating
HPC (gd), undiluted (9.5% HPC) – 0 0 0 slightly irritating
Toothgel with 1% HPC – 6 3 0 moderately irritating
Standard reference toothpaste (Sensodyne Fresh Mint) – 6 0 0 moderately irritating
Texapon ASV 5% (reference) 1.00 (±0.04) 12 10 0 moderately irritating
a Preserved.
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was chosen due to a broad experience with this model in our in-
house laboratories and well-established and reliable protocols.
HCE models were treated topically for 3 min with HPC (gd), HA-
NP, and HA-NN in concentrations of 0.5% and 1.0%. Following 18 h
of incubation, no signiﬁcant inﬂammatory or cytotoxic effects of
HPC or the other test samples were observed (Figs. 4 and 5). In
these experiments treatment with SDS as positive control lead to
an increased mean LDH value and a substantial amount of released
IL-1a in the culture medium. Although the mean value is clearly
elevated, this enhancement was not shown to be statistically
signiﬁcant.
The adverse effects of SDS could however be clearly demon-
strated in the histological evaluation, where SDS was shown to dis-
rupt the upper layers of the HCE model. The test samples, in
contrast, provided a vital picture composed of intact cells in differ-
ent layers as also seen in the untreated control (Fig. 6).
3.1.2.4. Macrophage assays. Rationale: Assessment of biocompati-
bility and information on biodegradability in case that part of the
material would be taken up systemically. Macrophage response0
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Fig. 3. MTT assay with 3T3 cells. Cell vitality was measured following treatment of 3T3 c
(n = 8 for HA-NP (gd) 1%, HPC (gd) 1%, HA-NN 1%. Statistical signiﬁcance of effects compar
sign-test for paired samples with alpha-correction. Following Friedman-ANOVA, signiﬁca
signiﬁcance: p < 0.0045 (alpha/11)).is considered essential since these cells represent the ﬁrst line of
defense and can mediate further processes. Macrophage assays
are well established to investigate the cytotoxic and inﬂammatory
potential of particles (Aam and Fonnum, 2007; Albrecht et al.,
2007; Balduzzi et al., 2004; Shamsuria et al., 2004). Activation of
macrophages is generally important to ensure that particles can
be taken up and degraded. The reaction however should not be
uncontrolled and not be persistent in order not to lead to adverse
effects.
Results of the macrophage assays were published previously. A
short summary of the results will be given here; for details we like
to refer to the original articles.
In a ﬁrst study (Scheel et al., 2009), RAW 264.7 macrophages
were incubated with HA-NR, HA-NP, HA-NN, and HPC in concentra-
tions from 50 to 5000 lg/ml. Cells were analyzed for viability (XTT-
test), cytokine production (TNF-a) and induction of nitric oxide
(NO) after 18 and 42 h with DQ12 quartz and lipopolysaccharide
(LPS) as positive controls. Viability was not considerably impaired
up to concentrations of 500 lg/ml by the test samples at both time
points and was overall about one order of magnitude higher than
with comparable concentrations of quartz. TNF-a release wasSD
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Fig. 4. LDH release from HCE models. LDH release from HCE models was detected following 3 min exposure with test samples and subsequent 18 h incubation. Data are
presented as mean ± SD (n = 8 for HA-NP (gd) 1%, HPC (gd) 1%, HA-NN 1%, untreated control; n = 5 for all other samples). Statistical signiﬁcance of effects in the different
treatment groups was tested by Kruskal–Wallis-ANOVA. No signiﬁcant differences between groups could be identiﬁed.
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Fig. 5. IL-1a release from HCE models. IL-a release from HCE models was detected following 3 min exposure with test samples and subsequent 18 h incubation. Data are
presented as mean ± SD (n = 8 for HA-NP (gd) 1%, HA-NN 1%, untreated control; n = 7 for HPC (gd) 1%; n = 5 for all other samples). Statistical signiﬁcance of effects in the
different treatment groups was tested by Kruskal–Wallis-ANOVA. Differences in signiﬁcance were initially indicated but not conﬁrmed in a subsequent Mann–Withney U test
(criterium for signiﬁcance: p 6 0.0083 (alpha/6)).
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pronounced induction at 100 lg/ml, still clearly below the LPS sig-
nal. No or little induction was observed after 42 h. NO production
was low at both time points.
In a second study (Albrecht et al., 2009), rat NR8383 macro-
phages and rat primary alveolar macrophages were incubated with
HA-NR, HA-NP, HA-NN, HA-FN and HPC in concentrations from 50 to5000 lg/ml with LPS and DQ12 quartz as positive controls. In WST-
1 and LDH assays with NR8383 cells, no cytotoxicity was observed
for HPC and other HA samples up to 3000 lg/ml, while HA-FN
showed a signiﬁcant effect at the highest dose in the LDH assay.
No cytotoxicity was observed in primary cells with all samples
up to 300 lg/ml. ROS generation was signiﬁcantly enhanced with
HA-NN and HPC in NR8383 cells in an EPR analysis. No effect was
Fig. 6. Histology of HCE models. Histology of HCE models treated with (a) 1% HPC
(gd), (b) 1% HA-NP (gd), (c) 1% SDS, (d) untreated. Parafﬁn slices were stained with
hematoxylin/eosin. The microscopic magniﬁcation was 20.
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physiological conditions. All HA samples elicited TNF-a release
from NR8383 cells with signiﬁcantly lower potency than the posi-
tive controls.
The combined results of both studies support the conclusion
that the tested HA materials exhibit a good biocompatibility and
are safe to use. Since the benchmark Ostim (HA-NN) as ofﬁcially
approved material is readily biodegradable and since HPC shows
similar effects, it can be assumed that HPC is biodegradable as well.3.1.3. Clinical studies
Rationale: (a) Investigation of product efﬁcacy of various formu-
lations with HPC (including toothpaste with 0.1% HPC) in the treat-
ment of dentine hypersensitivity and (b) conﬁrmation the results
of the initial risk assessment with regard to safety and tolerability
(the clinical studies were not designed to assess the hazard). With
regard to the scope of this publication only ﬁndings from (b) are re-
ported in the following.
Study 1: Only one adverse event (lumbago), which was not re-
lated to the treatment, was reported during the study. No clinically
relevant abnormalities were observed in bucco-dental examina-
tion during the study. The variations of gingival index were iso-
lated and were, therefore, not considered as clinically relevant.
Thus, both test toothpastes may be considered as having no inﬂam-
matory effect on gingiva. The change in teeth color was reported by
a small number of subjects equally distributed among the three
treatment groups whereas the amount of plaque remained un-
changed during the study.
The cosmetic acceptability questionnaire did not elicit negative
results with regard to side effects. Thus the overall acceptability
was considered to be very good for both toothpastes containing
HPC.Study 2: No clinically relevant abnormalities were observed in
bucco-dental examination during the study. No adverse events
were reported during the study. The use of the tooth-gel formula-
tion and the gel-strip product were safe and well tolerated.
In summary, no clinically relevant abnormalities were observed
in bucco-dental examination during both studies. The use of the
products was without unwanted side effects and well tolerated.3.1.4. Summary of hazard evaluation
Based on an initial assessment of supplier information and liter-
ature data no major concern was identiﬁed with regard to the safe
use of the constituents of HPC, hydroxyapatite and gelatin. How-
ever, there is evidence from the literature that in some test systems
small sizes of HA particles and speciﬁc morphologies could result
in different behavior like an increased inﬂammatory response (cf.
Section 3.1.1.1). Findings from a series of in vitro studies with
HPC and other HA materials supported the biocompatibility of
HPC with regard to cell viability, irritating effects, inﬂammation
and oxidative stress. Additional information was obtained from
clinical studies with HPC-containing formulations, such as tooth-
paste. No clinically relevant abnormalities were observed in buc-
co-dental examination during the studies. The use of the
products was without unwanted side effects and well tolerated.
The hazard to human health for the intended use in oral care for-
mulations is therefore considered to be low.3.2. Exposure analysis/toxicokinetics
The exposure analysis took the following elements into
account:
– What is the amount of HPC that is applied on a basis of daily
use?
– How much of HPC is likely to be swallowed?
– If swallowed, what is the fate of the material in the gastrointes-
tinal tract/in the body?
– If not swallowed, is it possible or likely that the material pene-
trates directly through the oral mucosa?
The concentration in currently marketed toothpastes of approx.
0.1% (corresponding to approx. 1% HPC (gd)) is used as a represen-
tative concentration for exposure calculations. Exposure through
inhalation is not considered since it is not expected under normal
use conditions. The building blocks of the assessment are outlined
in Fig. 1.3.2.1. General exposure estimate according to regulatory proposal
Rationale: Generic exposure estimate. The major part of the
product taken up by the consumer is expected to occur via the oral
route through potential swallowing of a small portion of the prod-
uct during application. To estimate this amount, the consumer
exposure was calculated according to average values provided by
the EU Commisson’s advisory panel (SCCP, 2006) which are similar
to the results of a study carried out by European cosmetic manu-
facturers (Hall et al., 2007).
Toothpaste with 0.1% HPC net content (adult): 1.4 g; two times/
day = 2.8 g/day.
Retention factor: 0.17.
Resulting amount: 0.48 g toothpaste/person/day.
Maximum amount of HPC after swallowing: 0.48 g  0.001 =
0.5 mg/person/day.
As a result, approximately 0.25 mg HPC per application may
reach the stomach.
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with oral mucosa)
3.2.2.1. Theoretical calculation. Rationale: This ‘‘worst-case’’ calcula-
tion was performed to estimate the maximum amount of HPC that
comes into contact with the mucosa in the oral cavity. In case of
100% penetration this would represent the maximum amount that
can be taken up systemically.
As outlined above (Section 3.2.1), the daily average amount of
HPC to come into contact with oral cavity can be calculated as fol-
lows: 2.8 g  0.001 = 3 mg. This represents the maximum amount
that could be taken up in the (theoretical) case of complete pene-
tration through the oral mucosa.
The potential distribution of HPC in the oral cavity can be calcu-
lated as well. The material is not expected to be signiﬁcantly dis-
solved in the oral cavity, where the pH typically ranges between
approx. 6 and 7.5. The total surface area (epithelium) of the oral
cavity in adult humans has been reported to be about 200 cm2
(Aframian et al., 2006). Provided that the complete epithelium
would come into contact with 3 mg HPC and would be evenly
spread, an amount per mucosal area of 0.015 mg HPC/cm2/day
can be calculated. (For comparison, the amount per area in the
HCE mucosa model experiments is within a range of 0.5–1 mg/
cm2.) It has to be considered that this represents a maximum
amount, since saliva (approx. 1 ml) will dilute the product, and a
large part of the product is expected to be disgorged after applica-
tion, or partly swallowed. This calculation is largely theoretical and
is not considered sufﬁcient for the exposure estimate.
3.2.2.2. Considerations regarding penetration based on literature and
expert consultation. Rationale: Estimation of the likelihood of direct
systemic uptake through the mucosa of the oral cavity via litera-
ture search and expert consultation.
Much of the literature dealing with the permeability of the oral
mucosa has been concerned with drug absorption; for review see
(Werner, 2003). Being more permeable, the non-keratinized areas
of the mucosa are of special interest for drug delivery. Buccal mu-
cosa contains intercellular lipids which are responsible for its
physical barrier properties, resulting in poor permeability for lar-
ger drug molecules such as peptides and proteins, requiring
absorption enhancers at molecular weights above 500–1000 Da.
The gelatin component in HPC has an average molecular weight
of 140,000 Da with a molecular weight distribution between ap-
prox. 6000 and >400,000 Da. It can therefore be assumed that
HPC agglomerates are not likely to penetrate oral mucosa.
Another important factor for enforced absorption/penetration
(of drugs) is a speciﬁc bioadhesivity towards the mucosa to over-
comewashing with saliva. In our experiments, the dispersion could
be readily rinsed from the mucosa models and did not apparently
adhere to the cells, as assessed by optical examination.
Though evidence is given that under normal conditions HPC is
not absorbed through healthy oral mucosa, the question could be
raised whether systemic exposure with small amounts of HPC
may occur, especially in case of mucosa damage, e.g. fresh wounds
after dental extraction and tissue damage following scaling, sub-
gingival irrigation or other therapeutical procedures, e.g.
(Schroeder, 2000). In such cases it cannot be ruled out that traces
of the material enter the blood circulation though normal physio-
logical defense mechanisms are likely to counteract potential up-
take through bleeding and coagulation. It can also be considered
that some oral diseases like periodontitis, gingivitis, neutropenia
and ulcerative mucositis can affect the permeability barrier of
the oral mucosa. For example, there are case reports that patho-
genic bacteria can reach the circulation of patients, e.g. (Ulstrup
and Hartzen, 2006).
Under most chronic disease conditions and with open wounds
however, the ﬂux is usually to the outside, thus counteractinguptake. In chronic inﬂammation states of the periodontium, the sul-
cus-ﬂux-rate (SFFR) is elevated – plasma release at the crevicular
epithelial cells (Sauerwein, 2000) – and considered to be an indica-
tor for inﬂammation. Various investigations (Del Fabbro et al.,
1998; Fjaertoft et al., 1992) have demonstrated that, on the one
hand, the number of inﬂammatory cells is increased in the connec-
tive tissue, and on the other hand, proteins can enter the gingiva-
sulcus through osmotic pressure with the emerging pressure gradi-
ent. Therefore, in the presence of chronic alterations of the perio-
dontium, it is very unlikely that HPC will reach the blood stream.
In conclusion, the risk of systemic exposure through lesions of
the periodontium or wounds is therefore considered very low.
(Dr. med. dent. L. Weber, Alderney Dental Practice, Poole, United
Kingdom, personal communication.)
3.2.2.3. Screening for possible translocation of HPC into cells or cell
layers using Cryo-TEM. Rationale: Exposure estimate through po-
tential direct penetration through the oral mucosa. This in vitro
screening experiment was performed to substantiate consider-
ations described under Section 3.2.2.2 as well as an observation
from the experiments with HCE models described in Section 3.1.2,
where optical inspection indicated that the test samples including
HPC can be easily rinsed off the models and are not sticky towards
the epithelium. As a consequence it was assumed that the penetra-
tion was not promoted and might even be absent or negligible.
A possible translocation of HPC into cells or cell layers in HCE
models was analyzed by Cryo-TEM following treatment with test
samples and rinsing as described in Section 2.5.2. Since the SkinE-
thic HCEmodel used for this investigation is non-keratinized, it can
be assumed that it resembles the non-keratinized (= more perme-
able) regions of the oral cavity.
Result: No indication for penetration of HPC into tissue and cells
could be detected in the TEM pictures, and only rarely with HA-NN
(pictures not shown).
3.2.3. Physico-chemical properties (dissolution kinetics)
Rationale: Generate information about the fate of HPC/HA in the
gastrointestinal tract. After swallowing the material enters
the stomach. Knowing that HA readily dissolves in acid medium,
the dissolution behavior of HPC in simulated gastric ﬂuid was
investigated.
It is commonly known that HA is nearly insoluble in aqueous
medium at alkaline or neutral pH but increasingly dissolves if
the pH goes down to the acid range. In particular, starting from
pH values of approx. 5 HA becomes increasingly soluble (Larsen
and Pearce, 1997), which is also utilized by macrophages for bio-
degradation of the material in the lysosomes (Bloebaum et al.,
1998; Motskin et al., 2009).
While the dissolution behavior may vary to a certain extent
depending on the presence of ions in the saliva (phosphate, ﬂuo-
ride, etc.), a ‘‘critical pH’’ for dissolution of hydroxyapatite in dental
enamel was determined to be at pH 5.1 (Ericsson, 1949); the most
often used reference value is 5.5 (Bardow et al., 2004; Larsen and
Pearce, 1997).
The average pH values in the acid medium of human stomach
are 1.7 (fasted), 1.9 (median posterior portion), 2.7 (median ante-
rior portion) or 5 (fed) (ECHA, 2007). The gastric emptying half-
time of solid meal was reported to be around 2 h (Yamada,
1999). It is therefore assumed that HA largely dissolves in the
stomach, even though the dissolution rate at fed conditions is ex-
pected to be lower than in the non-fed state. The gelatin compo-
nent, like other proteins, is expected to be cleaved by proteolytic
enzymes in the stomach.
A test with stimulated gastric ﬂuid (SGF) was conducted to ana-
lyze the speciﬁc dissolution behavior of HPC. No precipitation
could be detected following incubation with SGF. From the initial
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were identiﬁed in the aqueous medium and 39.5/42 mg in SGF.
The average recovery rate was 96.9%. It can therefore be expected
that the material readily dissolves in the stomach.
3.2.4. Summary exposure assessment
Systemic exposure through either oral uptake or direct contact
with the oral mucosa is considered to be very low. Exposure
through inhalation is not expected under normal use conditions.
Small amounts that are taken up through swallowing will be disin-
tegrated in the acid environment of the stomach and not be persis-
tent in a particulate form. A direct penetration through the mucosa
of the oral cavity is very unlikely as demonstrated by literature
data and supported by the results of an in vitro screening experi-
ment. In case trace amounts of particles would be taken up system-
ically, they can be degraded by macrophages in the acid
environment of lysosomes.
3.3. Risk assessment
Risk assessment is generally accomplished by a holistic view on
both hazard and exposure assessment and by coming up with a
conclusive statement on the estimated risk. As summarized above
(Section 3.1.4) the hazard of HPC can be considered as low due to
the various pieces of evidence generated by basic assessment of
available data, in vitro experiments and clinical studies. No concern
was raised in the basic assessment when considering the chemical
composition of the material and the toxicological proﬁle of its par-
ent compounds which both are naturally occurring and represent
the main component of teeth and bones in mammals. It could be
substantiated by the in vitro experiments and information from
clinical studies that the speciﬁc physico-chemical properties of
HPC are not leading to additional, unwanted effects at typical use
concentrations. Nevertheless, a thorough exposure assessment
was performed, leading to the conclusion that systemic exposure
can be considered negligible. Small amounts that might be swal-
lowed are likely to dissolve in the acid medium of the stomach. Di-
rect mucosal penetration seems to be unlikely, and in case traces of
HPC would become systemically available it can be assumed that
macrophages as the ﬁrst line of defense are well capable to process
and degrade the particles without leading to adverse effects. It is
concluded that the use of HPC in oral care formulations can be con-
sidered to be safe for the consumer.4. Discussion
A taylor-made risk assessment was designed for a hydroxyapa-
tite–protein-composite intended for use in oral care formulations
with a typical concentration of approx. 0.1% in toothpaste. Hazard
was analyzed by making use of a weight-of-evidence approach,
taking into account the physico-chemical properties, toxicological
information on the constituents, in vitro screening tests and clinical
studies with HPC without the need to perform new animal testing.
A major reason why such an approach could be successfully ap-
plied in this case is the fact that the constituents of HPC are well-
known substances with a long tradition of safe use and which
naturally occur in bones and teeth of mammals. In addition, con-
cerns often raised with potentially enhanced cytotoxic and inﬂam-
matory properties of small or nanosized particles could be
dispelled by the results of relevant in vitro screening experiments
which were additionally conﬁrmed in clinical studies.
Pure hydroxyapatite materials in the typical size range of a
nanomaterial (i.e. one or more dimensions below 100 nm) were in-
cluded in the majority of the in vitro tests. These materials behaved
largely similar in our test systems compared to particle sizes in themicrometer range. Interestingly, a meta-analysis of 49 studies
dealing with effects of particulate matter on cytokine production
in vitro revealed that results across cell types are relatively consis-
tent especially in the typically chosen concentration range be-
tween 50 and 100 lg/ml (Mitschik et al., 2008).
Broad experience is available regarding in vitro methods used
for the assessment, though individual methods may not be ofﬁ-
cially approved. For example, with regard to classiﬁcation purposes
under chemicals law for eye and mucous membrane irritation, only
few in vitro tests, including the HET-CAM, are accepted by author-
ities for screening but of severe irritants only (EU, 2009). In vitro
methods to detect these kind of effects nevertheless have a long-
standing history in the safety assessment of cosmetics, as reviewed
in (Eskes et al., 2005; McNamee et al., 2009). In addition, several
studies were published using the HET-CAM test to assess nanopar-
ticles and suspensions thereof in medical applications (Araujo
et al., 2009; Gupta et al., 2009; Pardeike and Muller, 2009; Wolf
et al., 2009).
Benchmark-based testing designs (in the current study we were
able to make use of an ofﬁcially approved medical product) and
inclusion of appropriate controls are necessary tools to make rea-
sonable use of the results, in particular in cases where no absolute
thresholds are established to judge on adversity of effects.
Obviously, known or potential limitations of individual test
methods need to be considered. Electron microscopy, for example,
commonly provides detail snapshots on the analyzed items. Suit-
able TEM approaches for quantifying particles in tissues are being
explored and so far have proven to be very complex (Mayhew
et al., 2009). Also, methods to measure cell viability can be inﬂu-
enced by various parameters. Therefore combination of different
cell viability methods and cellular systems which may differ in
sensitivity enhances the overall quality of information. Cell viabil-
ity was not severely impaired in any of the different test systems
used in this study but slight differences could be observed in some
cases. Regarding the comparability of MTT and LDH, others re-
ported that MTT and LDH results did not correlate well when
assessing ﬁne and nanoparticle effects in lung cell cultures (Sayes
et al., 2007).
The use of in vitro systems will beneﬁt from further standardi-
zation of protocols, data interpretation and validation, especially
with regard to a quantitative extrapolation to physiological effects
in vivo. This is important to promote their broad use and accep-
tance in regulatory risk assessments. It was demonstrated that
already today they can serve as useful elements in a weight-of-evi-
dence approach.
Research on the effects of particulates is ongoing within the sci-
entiﬁc community comprising the investigation of particulate up-
take into living organisms and fate in the human body like
accumulation in speciﬁc organs. A thorough exposure analysis as
included in the current assessment therefore is indispensable even
if a low hazard is expected. Beyond the standard exposure esti-
mate, additional considerations on biodegradability were included
due to the particulate nature of the material. Numerous publica-
tions conﬁrm the biodegradability of the hydroxyapatite compo-
nent, while gelatin can be assumed to be cleaved in the stomach.
Additional information might however be needed in such cases
where particles are persistent and therefore may have the poten-
tial to induce prolonged inﬂammation, oxidative stress or dislocate
to different compartments in the body.
With the integrated assessment as it was described here for
HPC, one of the major scientiﬁc and ethical objectives of the EU
and beyond, i.e. the use of alternative methods to the current
animal tests for risk assessment is pursued (cf. Directive
EC86/609). For each new material it needs to be investigated
if a similar approach is appropriate based on the actual state-
of-the-art.
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Based upon the presented experimental results and considering
the data on the constituents, it can be concluded that HPC does not
pose a concern to human health for the intended use in oral care
formulations. This strategy provides an example of a risk assess-
ment for a cosmetic use of small particles without the need to per-
form additional animal studies. In vitro screening tools are already
capable to serve as useful elements of weight-of-evidence assess-
ments and should be further developed and used for such
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